Skip to content
LexBuild

Withdrawal of Approval of New Animal Drug Applications; Ketamine; S-Methoprene; Nitazoxanide

---
identifier: "/us/fr/E9-17408"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Withdrawal of Approval of New Animal Drug Applications; Ketamine; S-Methoprene; Nitazoxanide"
title_number: 0
title_name: "Federal Register"
section_number: "E9-17408"
section_name: "Withdrawal of Approval of New Animal Drug Applications; Ketamine; S-Methoprene; Nitazoxanide"
positive_law: false
currency: "2009-07-22"
last_updated: "2009-07-22"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "E9-17408"
document_type: "notice"
publication_date: "2009-07-22"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "74 FR 36241"
fr_volume: 74
docket_ids:
  - "Docket No. FDA-2009-N-0302"
effective_date: "2009-08-03"
fr_action: "Notice."
---

#  Withdrawal of Approval of New Animal Drug Applications; Ketamine; S-Methoprene; Nitazoxanide

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The Food and Drug Administration (FDA) is withdrawing approval of two new animal drug applications (NADAs) and an abbreviated new animal drug application (ANADA) listed in table 1 of this document. In a final rule published elsewhere in this issue of the *Federal Register* , FDA is amending the animal drug regulations to remove portions reflecting approval of these NADAs and ANADA.

**DATES:**

Withdrawal of approval is effective August 3, 2009.

**FOR FURTHER INFORMATION CONTACT:**

John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, e-mail: *[email protected]* .

**SUPPLEMENTARY INFORMATION:**

The following sponsors have requested that FDA withdraw approval of the two NADAs and ANADA listed in table 1 of this document because the products are no longer manufactured or marketed:

| Sponsor | NADA/ANADA Number | 21 CFR Cite Affected |
| --- | --- | --- |
| Wellmark International, 1501 East Woodfield Rd., suite 200, West Schaumburg, IL 60173 | NADA 141-162 | 520.1390 (011536) |
| IDEXX Pharmaceuticals, Inc., 7009 Albert Pick Rd., Greensboro, NC 27409 | NADA 141-178 | 520.1498 (065274) |
| Abbott Laboratories, North Chicago, IL 60064 | ANADA 200-279 | 522.1222a (000074) |

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 *Notice of withdrawal of approval of application* (21 CFR 514.116), notice is given that approval of NADAs 141-162 and 141-178, and ANADA 200-279, and all supplements and amendments thereto, are hereby withdrawn, effective August 3, 2009.

In a final rule published elsewhere in this issue of the *Federal Register* , FDA is amending the animal drug regulations to reflect the withdrawal of approval of these NADAs.

Dated: July 14, 2009.

Bernadette Dunham,

Director, Center for Veterinary Medicine.